Janux Therapeutics Files 8-K
Ticker: JANX · Form: 8-K · Filed: Dec 5, 2024 · CIK: 1817713
| Field | Detail |
|---|---|
| Company | Janux Therapeutics, Inc. (JANX) |
| Form Type | 8-K |
| Filed Date | Dec 5, 2024 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001, $63.00, $62.999, $350.0 m |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, SEC Filing, Corporate
TL;DR
Janux Therapeutics filed an 8-K on Dec 4, 2024. Standard filing, no major news yet.
AI Summary
On December 4, 2024, Janux Therapeutics, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific material events detailed in the provided text. The company is incorporated in Delaware and its principal executive offices are located in San Diego, California.
Why It Matters
This 8-K filing indicates that Janux Therapeutics, Inc. has submitted a report to the SEC, which may contain updates or disclosures relevant to investors.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report with no immediately disclosed material events, suggesting a low immediate risk based on this information alone.
Key Numbers
- 001-40475 — SEC File Number (Identifies the company's filing with the SEC.)
- 82-2289112 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Janux Therapeutics, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of Incorporation
- San Diego, California (location) — Principal Executive Offices
- December 4, 2024 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing for Janux Therapeutics, Inc.?
The filing is a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting 'Other Events' and 'Financial Statements and Exhibits'.
When was the earliest event reported in this filing?
The earliest event reported is dated December 4, 2024.
Where are Janux Therapeutics, Inc.'s principal executive offices located?
The principal executive offices are located at 10955 Vista Sorrento Parkway, Suite 200, San Diego, California, 92130.
What is the company's state of incorporation?
Janux Therapeutics, Inc. is incorporated in Delaware.
What is the SEC file number for Janux Therapeutics, Inc.?
The SEC file number is 001-40475.
Filing Stats: 1,174 words · 5 min read · ~4 pages · Grade level 10.6 · Accepted 2024-12-05 16:32:31
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share JANX Nasdaq Glo
- $63.00 — "Shares"), at a price to the public of $63.00 per share, and pre-funded warrants to p
- $62.999 — ommon stock at a price to the public of $62.999 per pre-funded warrant, which is the pr
- $350.0 m — from the Offering will be approximately $350.0 million, before deducting underwriting di
Filing Documents
- d877731d8k.htm (8-K) — 33KB
- d877731dex11.htm (EX-1.1) — 230KB
- d877731dex41.htm (EX-4.1) — 71KB
- d877731dex51.htm (EX-5.1) — 14KB
- d877731dex991.htm (EX-99.1) — 9KB
- d877731dex992.htm (EX-99.2) — 9KB
- g877731g01m94.jpg (GRAPHIC) — 3KB
- 0001193125-24-271578.txt ( ) — 592KB
- janx-20241204.xsd (EX-101.SCH) — 3KB
- janx-20241204_lab.xml (EX-101.LAB) — 18KB
- janx-20241204_pre.xml (EX-101.PRE) — 11KB
- d877731d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 1.1 Underwriting Agreement, dated December 4, 2024, by and among Janux Therapeutics, Inc. and BofA Securities, Inc., TD Securities (USA) LLC, Stifel, Nicolaus & Company, Incorporated, Cantor Fitzgerald & Co. and William Blair & Company, L.L.C. as representatives of the several underwriters named therein. 4.1 Form of Pre-Funded Warrant. 5.1 Opinion of Cooley LLP. 23.1 Consent of Cooley LLP (included in Exhibit 5.1). 99.1 Press Release, dated December 3, 2024. 99.2 Press Release, dated December 4, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
Forward-Looking Statements
Forward-Looking Statements
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. JANUX THERAPEUTICS, INC. Date: December 5, 2024 By: /s/ David Campbell, Ph.D. David Campbell, Ph.D. Chief Executive Officer